New lupus drug shows early promise in small trial
NCT ID NCT05638802
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested an experimental drug called DS-7011a in 26 adults with systemic lupus erythematosus (SLE), a chronic autoimmune disease. The study aimed to check the drug's safety and how the body processes it, not yet to prove it works. Participants received either the drug or a placebo intravenously every 4 weeks for three doses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DS-7011a (an experimental drug given intravenously)
What this could lead to
If successful, this could point toward a new treatment option for lupus that is safer and more effective than current therapies.
What could go wrong
This is a very early, small study (26 people) focused on safety and dosing, not on proving the drug works. Many promising early-stage drugs fail in larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arkansas Research Trials
North Little Rock, Arkansas, 72117, United States
-
Hospital of the University of Occupational and Environmental Health
Kitakyushu-shi, 807-8556, Japan
-
Japan Community Health Care Organization Chukyo Hospital
Nagoya, 457-8510, Japan
-
Jcho Tokyo Yamate Medical Center
Shinjuku-ku, 169-0073, Japan
-
Joint & Muscle Research Institute
Charlotte, North Carolina, 28204, United States
-
MediSearch Clinical Trials
Saint Joseph, Missouri, 64506, United States
-
Metroplex Clinical Research Center, LLC
Dallas, Texas, 75231, United States
-
Oakland Hills Dermatology
Auburn Hills, Michigan, 48326, United States
-
Office of Tory P. Sullivan, M.D. - North Miami Beach
North Miami Beach, Florida, 33162, United States
-
Phi University Clinic of Rheumatology Skopje
Skopje, 1000, North Macedonia
-
Pinnacle Research Group LLC
Anniston, Alabama, 36207, United States
-
Precision Comprehensive Clinical Research Solutions
Colleyville, Texas, 76034, United States
-
Renji Hospital Shanghai Jiaotong University School of Medicine - West Branch
Shanghai, 200001, China
-
Revival Research Institute, LLC
Troy, Michigan, 48084, United States
-
The University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
-
Tohoku University Hospital
Sendai, 980-8574, Japan
-
Trinity Health Center Medical Arts
Minot, North Dakota, 58701, United States
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, 430022, China
-
West Broward Rheumatology Associates
Tamarac, Florida, 33321, United States
-
Yokohama City University Medical Center
Yokohama, 232-0024, Japan